27 August 2024
Belluscura plc
("Belluscura" or the "Company")
Result of General Meeting
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that at the Annual General Meeting held earlier today, all resolutions proposed were duly approved by shareholders:
|
Total votes for |
% of shares voted |
Total votes against |
% of shares voted |
Total votes |
Votes withheld |
Ordinary resolutions |
|
|
|
|
|
|
Resolution 1: To receive and adopt the report of the directors and the audited accounts of the Company for the period ended 31 December 2023 |
91,444,802 |
99.94 |
55,722 |
0.06 |
91,500,524 |
- |
Resolution 2: To re-elect Simon Neicheril as a director of the Company |
91,426,718 |
99.94 |
54,753 |
0.06 |
91,481,471 |
19,053 |
Resolution 3: To re-elect Robert Fary as a director of the Company |
91,426,718 |
99.94 |
54,753 |
0.06 |
91,481,471 |
19,053 |
Resolution 4: To re-elect Paul Tuson as a director of the Company |
91,426,574 |
99.94 |
54,897 |
0.06 |
91,481,471 |
19,053 |
Resolution 5: To re-appoint Gerald Edelman LLP as auditor to the Company |
91,456,503 |
99.95 |
43,877 |
0.05 |
91,500,380 |
144 |
Resolution 6: To authorise the directors to determine the remuneration of the auditors |
91,442,594 |
99.96 |
38,877 |
0.04 |
91,481,471 |
19,053 |
Resolution 7: To grant the directors authority to allot shares pursuant to Section 551 of the Companies Act 2006 and grant rights to subscribe for, or convert any security into, shares |
91,439,344 |
99.93 |
61,180 |
0.07 |
91,500,524 |
- |
Special resolutions |
|
|
|
|
|
|
Resolution 8: To dis-apply pre-emption rights pursuant to Section 570 of the Companies Act 2006 |
86,818,255 |
94.90 |
4,663,216 |
5.10 |
91,481,471 |
19,053 |
Resolution 9: To authorise the directors to make market purchases |
86,896,258 |
94.97 |
4,604,266 |
5.03 |
91,500,524 |
- |
For further information please contact:
Belluscura plc |
Tel: +44 (0)20 3128 8100 |
Adam Reynolds, Chairman Robert Rauker, Chief Executive Officer Simon Neicheril, Chief Financial Officer |
|
|
|
SPARK Advisory Partners Limited (Nominated Adviser) |
Tel: +44 (0)20 3368 3550 |
Neil Baldwin / Jade Bayat |
|
|
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
James Serjeant / Russell Cook |
|
|
|
MHP Group (Financial PR & Investor Relations) |
Tel: +44 (0)20 3128 8100 |
Katie Hunt / Matthew Taylor |
belluscura@mhpgroup.com |
About Belluscura plc (https://belluscura.com/)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.